Seven new leaders have been appointed to guide Vanderbilt-Ingram Cancer Center's research programs.

Immunotherapy in combination with chemotherapy has become an important therapeutic treatment option in some patients with metastatic breast cancer. Which patients will benefit the most, however, remains unclear; current biomarkers such as PD-L1 that are used to predict response are mediocre at best. 

Nicole Kidman and Keith Urban have made a generous financial gift to Vanderbilt-Ingram Cancer Center in support of clinical trials for new and better therapies for breast cancer.

Vanderbilt research shows that a liquid biopsy-based multicancer early detection (MCED) test could detect 12 types of cancers, including low DNA-shedding cancers and early-stage cancers.

The expected course of a patient's cancer prognosis has traditionally been judged by its type, stage and microscopic aggressiveness, but patients with the same presentation can still have widely divergent outcomes. Researchers from Vanderbilt-Ingram Cancer Center have discovered that differences in tumor mutation burden are a major reason for this divergence.

A broad bioinformatics approach revealed that Hedgehog signaling is upregulated in dedifferentiated liposarcoma, suggesting this pathway may be an early indicator of poor prognosis and a potential therapeutic target.

International workgroup issues additional guidance on how to manage patients who carry inherited CHEK2 gene mutations that put them at a higher risk for cancer.

Vanderbilt researchers have discovered a druggable target on natural killer cells that could potentially trigger a therapeutic response in patients with immunotherapy-resistant, triple-negative breast cancer.

Newer treatments, the importance of early detection, and how comprehensive breast centers can help.

International workgroup issues additional guidance on how to manage patients who carry inherited CHEK2 gene mutations that put them at a higher risk for cancer.